Retatrutide
Triple GLP Receptor Agonist · LY3437943 · Research Use Only
Retatrutide is a first-in-class triple hormone receptor agonist developed by Eli Lilly, simultaneously activating GIP, GLP-1, and glucagon receptors. It represents the most advanced metabolic research compound available, surpassing single and dual receptor agonists in Phase 2 and Phase 3 clinical research for percentage body weight reduction.
How it works: GLP-1 receptor activation suppresses appetite via hypothalamic signaling. GIP receptor activation enhances insulin sensitivity and modulates adipose tissue metabolism. Glucagon receptor activation drives thermogenesis and increases energy expenditure. Together, this triple agonism creates a complementary hormonal cascade that no single or dual agonist can replicate.
Research highlights:
- NEJM Phase 2 (2023): 24.2% average body weight reduction at 12mg over 48 weeks vs 2.1% placebo
- TRIUMPH-4 Phase 3 (2025): 28.7% average weight loss at 68 weeks
- Nature Medicine (2024): 86% of participants achieved normal liver fat at 12mg dose vs 0% placebo
Molecular Formula: C₂₁₂H₃₃₁N₅₇O₆₅
Molecular Weight: 4731.3 g/mol
Form: Lyophilized powder
Purity: ≥98% (HPLC verified)
Storage: -20°C, away from light and moisture
⚠ RESEARCH USE ONLY. This product is intended for laboratory and in vitro research purposes only. Not for human or animal consumption. Must be 21+ to purchase. These statements have not been evaluated by the FDA.